Registry data taken from the Center for International Blood and Marrow Transplant Research (CIBMTR) on the utilization of CD19 CAR-T therapy for R/R pediatric B-ALL revealed outcomes that are comparable to those of clinical trials, with a CR rate of 85.5%, 99.1% of whom were MRD-negative. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.